Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients…

By G. Lenz, M. Dreyling, E. Hoster, B. Wörmann, U. Dührsen, B. Metzner, H. Eimermacher, A. Neubauer, H. Wandt, H. Steinhauer and 7 more. Journal of Clinical Oncology, 2005

613 citations recorded by the source corpus.

Subfields: Dermatology, Neurology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/21b79dd30dc232dc34f3c15d86a96e1afdf78097

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. R. Fisher
2. S. Lonial
3. A. Goy
4. J. Leonard
5. O. O'Connor
6. Hongliang Shi
7. A. Boral
8. E. Stadtmauer

Citations in the corpus

• A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. (2006, neutral): “Median platelet count, 109/L (range) 188 (3-1346) 452”
• Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. (2004, neutral): “High-intermediate risk 6 (11) 6 (11) 12 (11)”
• Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. (2006, background): “Medianfailure-freesurvival isapproximately 8 to 20 months with standard therapies,(6,16-19) although longer survival has been reported with highintensityregimens.(11-14,16,18)Mediansurvivalisapproximately 3 to 4 years with standard treatment.”